ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The study will be conducted in a respiratory specialist institute in Japan, with standardized
techniques and data assurance checks to optimize data quality. The licensed dosage and
administration of Adoair in Japan will be applied in this study. Each subject will receive
treatment options in a randomized blinded fashion. Subjects will be randomized following a
4-week wash-out phase to take either Adoair 50/250mcg twice daily or placebo twice daily for
12 weeks.